Effective immediately, Symtomax will distribute on a white-label basis Greater Cannabis Company’s oral eluting patch, transdermal patch, and other proprietary technologies and products across its distribution network that spans across Europe, the Middle East and Africa. Additional geographic and product expansion plans are expected to be added as the two companies begin implementing the initial phases of this agreement.